Skip to Content

Triazolam Pregnancy and Breastfeeding Warnings

Triazolam is also known as: Halcion

Triazolam Pregnancy Warnings

Animal studies have shown evidence of retarded or impaired skeletal formation, and impaired viability and weight gain. There are no controlled data in human pregnancy. Benzodiazepines cross the placenta and may cause hypotonia, respiratory depression, and hypothermia in the newborn infant. Withdrawal symptoms in newborn infants have been reported with this class of drug. Also, neonatal flaccidity has been reported in an infant born of a mother who had been receiving benzodiazepines. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Use is contraindicated AU TGA pregnancy category: C US FDA pregnancy category: X

See references

Triazolam Breastfeeding Warnings

Use should be avoided; use of this drug during lactation is contraindicated in Australia. Excreted into human milk: Unknown Excreted into animal milk: Yes

Little information is available on the use of triazolam during breastfeeding; an alternate short-acting hypnotic may be preferred (e.g., oxazepam or lorazepam), particularly when nursing a newborn or preterm infant. Because of its relatively short half-life, occasional use of triazolam during breastfeeding in an older infant should pose little risk; however, the infant should be monitored for excessive drowsiness.

See references

References for pregnancy information

  1. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. Department of Adolescent and Child Health and Development. UNICEF. World Health Organization "Breastfeeding and maternal medication: recommendations for drugs in the eleventh Who model list of essential drugs. Available from: URL:" ([2003]):
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.